SciELO - Scientific Electronic Library Online

 
vol.4 número2Un caso de intoxicación por fosfuro de aluminio manejado con éxito en Nepal: informe de un caso índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Iberoamerican Journal of Medicine

versión On-line ISSN 2695-5075versión impresa ISSN 2695-5075

Iberoam J Med vol.4 no.2 Logroño may. 2022  Epub 04-Dic-2023

https://dx.doi.org/10.53986/ibjm.2022.0013 

Clinical Image

Graves' ophtalmopathy

Oftalmopatía de Graves

Satvinder Bakshi1  saty.bakshi@gmail.com

1All India Institute of Medical Sciences Mangalagiri, India

Keywords Graves' ophtalmopathy; Graves' disease; Hyperthyroidism

Palabras clave Oftalmopatía de Graves; Enfermedad de Graves; Hipertiroidismo

A 45-year-old female patient suffering from Graves's disease presented with dryness, blurring of vision, and protrusion of her eyes for 2 months. Ocular examination revealed bilateral proptosis with the widening of the palpebral fissure and retraction of both upper and lower eyelids (Dalrymple's sign) (Figure 1). She also had upper lid lag on looking down (Von Graefes sign), lower lid lag on looking up (Griffith sign), deficient convergence (Mobius sign), and infrequent blinking (Stellwag's sign). In addition, there was decreased visual acuity and restriction in extraocular movements in both eyes. The patient was started with carbimazole and propranolol, lubricating eye drops, gel, and intravenous methylprednisolone pulse therapy. At 3 months, follow up her thyroid profile was normal and proptosis had reduced.

Figure 1. Patient with bilateral proptosis and widening of the palpebral fissure and retraction of both upper and lower eyelids (Dalrymple's sign). 

Graves ophtalmopathy (GO) is the most common extrathyroidal manifestation of Graves' disease (GD) characterized by immunological to the thyroid-stimulating hormone receptor (TSH-R) [1]. Most patients are hyperthyroid. However, some may be euthyroid. The incidence of GO is 16 women or 3 men per 100,000 person per year. The pathogenesis comprises (1) inflammation of the periorbital soft tissues; (2) overproduction of glycosaminoglycans by orbital fibroblasts; and (3) hyperplasia of adipose tissue.2 The extracellular matrix rich in glycosaminoglycans makes it highly hydrophilic, increasing its capacity to retain water making the extraocular muscles swell dramatically. In addition, adipogenesis also results in increased orbital tissue volume [2]. There are two stages in the natural history of GO: the first one is the active stage, observing an increased inflammation and rapid progression; it is followed by an inactive phase (second stage) in which the inflammatory signs and symptoms gradually reduce. However, the muscular edema along with increased production of collagen ultimately lead to fibrosis and sclerosis resulting in restrictive strabismus, proptosis and persistent lid retraction. The treatment depends on the stage, in the active stage anti-inflammatory treatment with glucocorticoids, cyclosporine, or mild low dose radiation is carried out, in sight-threatening cases orbital decompression should be carried out [3]. In the inactive stage, rehabilitative surgery like eyelid and strabismus correction can be done [2].

CONFLICT OF INTERESTS

The authors have no conflict of interest to declare. The authors declared that this study has received no financial support.

REFERENCES

1. Bahn RS. Current Insights into the Pathogenesis of Graves' Ophthalmopathy. Horm Metab Res. 2015;47(10):773-8. doi: 10.1055/s-0035-1555762.Links ]

2. Wiersinga WM. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy. Lancet Diabetes Endocrinol. 2017;5(2):134-42. doi: 10.1016/S2213-8587(16)30046-8.Links ]

3. Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velázquez-Villoria Á, Galofré JC. Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. J Ophthalmol. 2015;2015:249125. doi: 10.1155/2015/249125.Links ]

Received: January 19, 2022; corrected: February 24, 2022; Accepted: February 26, 2022

Creative Commons License This is an open access article under the CC BY license